Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 1 ... and CEO, Edwards Lifesciences, John C. Martin, Ph.D., chairman of the board and CEO, GileadSciences and Mark D. Smith, M.D., M.B.A., president and CEO, California HealthCare ...
2009 NOV 16 ... and CEO, Edwards Lifesciences; and John C. Martin, Ph.D., chairman of the board and CEO, GileadSciences. "The biomedical community is eager to work with policy makers to ...
2009 NOV 16 ... also a co-founder of Myogen Inc., a highly successful CU spin-out that was acquired by Gilead for $70 million. Following the acquisition of Myogen, she began Hiberna Corporation ... order to foster new research, teaching and technology development in the fields of life sciences, physical sciences, math, computational sciences and engineering which is on the cutting ...
2009 OCT 19 ... PriceWatch Alerts cover the following stocks: United States Steel Corp. (NYSE:X), Gilead Sciences Inc. (NASDAQ:GILD), The Dow Chemical Company (NYSE:DOW), Banco Bradesco S.A. (NYSE:BBD), and ...
2009 OCT 19 ... including Atripla®, which combines drugs from Bristol-Myers Squibb (NYSE:BMY) and GileadSciences (NasdaqGS:GILD); Viracept® from Pfizer (NYSE:PFE); and Norvir® from ... In response to new economic and regulatory realities, CytoDyn, Inc. (Pink Sheets:CYDY) has made a sea change in its strategy for developing Cytolin®, ...
2009 NOV 10 ... and will receive "Financier of the Year Award." The "Global Reach Award" goes to GileadSciences, a leader in HIV/AIDS treatments, for its affordable care and treatment ...
2009 OCT 5 ... California Healthcare Policy Forum to Oct. 2. The forum, hosted by CHI and supported by GileadSciences, Sanofi-Aventis and Exelixis, will be held Nov. 5, in San Francisco, at the ...
2009 NOV 16 ... U.S. Food and Drug Administration, Viread, ViroLogic Inc., Virology, Women's Health, Gilead Sciences Inc. This article was prepared by AIDS Weekly editors from staff and other ...
2009 NOV 16 ... Post-Trial Research, Pulmonology, Tadalafil, Therapy, Treatment, Vomiting, Gilead Sciences Inc. This article was prepared by Pain & Central Nervous System Week editors ...
2009 NOV 2 ... Therapy, Treatment, Truvada, Viral Inhibition, Viral Therapy, Viread, Virology, Gilead Sciences Inc. This article was prepared by Pain & Central Nervous System Week editors ...
2009 NOV 23 ... company of GTCR Golder Rauner, LLC, announced that the company has acquired from GileadSciences, Inc. the worldwide license, including related regulatory filings and ...
2009 NOV 2 ... and CEO, Edwards Lifesciences; John C. Martin, Ph.D., chairman of the board and CEO, GileadSciences; and Mark D. Smith, M.D., M.B.A., president and CEO, California HealthCare ...
2009 OCT 12 ... and CEO, Edwards Lifesciences; John C. Martin, Ph.D., chairman of the board and CEO, GileadSciences; and Mark D. Smith, M.D., M.B.A., president and CEO, California HealthCare ... has headed Edwards Lifesciences since it was spun off from Baxter International Inc. and began operating as an independent, publicly traded company in April 2000. He ...
2009 OCT 5 ... nebuliser for cystic fibrosis and has been specifically developed to deliver GileadSciences' Cayston. Cayston, aztreonam lysine 75 mg powder and solvent for nebuliser ...
2009 NOV 9 ... and CEO, Edwards Lifesciences, John C. Martin, Ph.D., chairman of the board and CEO, GileadSciences and Mark D. Smith, M.D., M.B.A., president and CEO, California HealthCare ...
2009 NOV 23 ... drugs, fluid management with effective diuretic therapy might be needed. Funding GileadSciences." Weber and colleagues published their study in Lancet (A ... The publisher of the journal Lancet can be contacted at: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA. Keywords: City:Box, ...
2009 SEP 28 ... with high activity in vitro and in vivo," wrote D.L. MacLeod and colleagues, GileadSciences, Inc. The researchers concluded: "These data suggest FTI could be ...
